Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effect of Lanabecestat on the Pharmacokinetics of Ethinyl Estradiol and Levonorgestrel in Healthy Female Subjects

Trial Profile

Effect of Lanabecestat on the Pharmacokinetics of Ethinyl Estradiol and Levonorgestrel in Healthy Female Subjects

Status: Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 06 Jul 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lanabecestat (Primary) ; Ethinylestradiol/levonorgestrel
  • Indications Alzheimer's disease
  • Focus Pharmacokinetics
  • Sponsors Eli Lilly
  • Most Recent Events

    • 26 Jun 2018 Planned End Date changed from 19 Oct 2018 to 1 Oct 2018.
    • 26 Jun 2018 Planned primary completion date changed from 19 Oct 2018 to 1 Oct 2018.
    • 26 Jun 2018 Planned initiation date changed from 14 Jun 2018 to 1 Jun 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top